3 Large-Cap Stocks That Should Soar If Coronavirus Vaccines Flop

It seems to be a foregone conclusion that at least one COVID-19 vaccine will be available by sometime next year. Twenty-six vaccine candidates are currently in clinical testing with more likely on the way. Six candidates are already in late-stage clinical trials.

But what if the optimistic projections turn out to be wrong? Here are three large-cap stocks that should soar if coronavirus vaccines flop…

1. Gilead Sciences

Gilead Sciences‘ (NASDAQ:GILD) remdesivir demonstrated the potential to improve the prospects for hospitalized patients with COVID-19 to recover more quickly in phase 3 clinical studies. The antiviral drug is available in the U.S. under an emergency use authorization (EUA) granted by the FDA and has been approved by regulatory agencies in Europe and Japan.

The big biotech stands to make in the ballpark of $3.5 billion this year from sales of remdesivir. However, there are some questions about how much money Gilead will make over the long run from remdesivir once coronavirus vaccines are available.

Any delay in the approvals of COVID-19 vaccines would almost certainly boost sales for remdesivir. Gilead’s revenue would be even higher if clinical studies evaluating an inhaled version of the drug are successful. With potentially billions of dollars in extra revenue, the biotech stock would be a sure-fire winner should COVID-19 vaccine candidates stumble in clinical testing.

2. Eli Lilly

Eli Lilly (NYSE:LLY) hasn’t won regulatory approval or EUA for any of its investigational COVID-19 therapies so far. But that could change in the not-too-distant future.

The big drugmaker began a phase 3 clinical study in June evaluating arthritis drug Olumiant in treating COVID-19. Another study of the drug in combination with Gilead’s remdesivir is being conducted by the National Institutes of Health (NIH).

Lilly recently started a phase 3 study of experimental antibody therapy LY-CoV555 in preventing COVID-19 in long-term care facilities. The NIH also just kicked off another late-stage study featuring the therapy. The company is also evaluating the candidate in treating hospitalized patients with COVID-19 and treating patients in ambulatory settings in earlier-stage studies. In addition, Lilly is preparing to advance antibody therapy candidate LY-CoV016 into the next stage of clinical development after obtaining positive results in a phase 1 study.

There’s no guarantee that all of these candidates will be successful. But serious problems for COVID-19 vaccines would likely translate to increased interest in Lilly’s coronavirus programs — and provide a solid catalyst for the pharma stock.

3. Abbott Labs

Abbott Labs (NYSE:ABT) made headlines earlier this year with the launch of its COVID-19 diagnostic test for its ID NOW platform. The test can deliver positive results in as little as five minutes and negative results in around…

Continue reading at THE MOTLEY FOOL